SCR
| Symbol |
last price |
date |
time |
change |
open |
high |
low |
volume |
P/E (ttm) |
P/E (Forward) |
| SCR |
9.05 |
9/2/2010 |
2:54pm |
-0.04 |
9.08 |
9.22 |
9.03 |
20208 |
|
|
Summary
Simcere Pharmaceutical Group, through its subsidiaries, engages in the manufacture and supply of branded generic pharmaceuticals in the People's Republic of China. It manufactures and sells 35 pharmaceutical products and distributes 3 additional pharmaceuticals under its brand names. The company's products include antibiotics, an anti-stroke medication, anti-inflammatory pain relievers, an anti-cancer medication, and other pharmaceuticals. Its principal branded generic pharmaceutical products comprise edaravone injection under the name Bicun; amoxicillin capsules, dispersible tablets, granules, and injection under the brand Zailin; amoxicillin with clavulanate potassium granules, tablets, and injection under the name Anqi; diclofenac sodium sustained-release capsules and gelatin under the brand Yingtaiqing; and smectite powder under the name Biqi. The company distributes prescription pharmaceuticals manufactured by independent third parties, including generic diclofenac sodium sustained-release capsules under the brand Yingtaiqing, generic alfacalcidol soft capsules under the name Faneng, and generic lentinan injection under the brand Yineng. As of March 20, 2007, it also had 12 product candidates in various stages of development, including treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, nasal allergies, and nausea and vomiting associated with chemotherapy. Simcere Pharmaceutical Group markets and sells its products to approximately 900 regional pharmaceutical distributors, who in turn sell these products to local distributors, hospitals, and retail pharmacies. The company was founded in 1995 and is headquartered in Nanjing, the People's Republic of China.